I almost sense they meant to "accidentally" release the info prematurely.
I keep getting an error message
With a $1 billion market cap,this is a $12 stock. $1 billion is still a very small cap for a biotech.
Looks like the sub $1 days are gone.
Start of page content Return to search Page to restart searchReturn to Orphan Designation Search PageReturn to Search Page
Row Num Generic Name Designation Date Orphan Designation
1 Detailed Record for Productpelareorep 02-10-2015 Treatment of ovarian cancer
2 Detailed Record for Productpelareorep 02-24-2015 Treatment of primary peritoneal cancer
3 Detailed Record for Productpelareorep 02-24-2015 Treatment of fallopian tube cancer
4 Detailed Record for Productpelareorep 02-11-2015 Treatment of pancreatic cancer
yup currently- HTB- hard to borrow
Regulatory circuit breaker is on. If a security falls/rises 10% in a 5-minute period a market-wide trading phase will occur in the security for a full 5 minutes. Bottom line, this is ready to go parabolic tomorrow.
Cytori: No Smoke without Fire
Cytori (CYTX: NASDAQ, $ 1,14), BUY
Within just a few days, Cytori shares more than doubled from $ 0.50 to more than $ 1.10.
Yesterday more than 40mn shares were traded, almost half of the total number of shares outstanding.
I did expect recovery potential (see blog: bombed out stocks with recovery potential, 08.01.2015), but was completely surprised how fast the recovery took place. Especially, as there was some positive news flow, but nothing to justify such a rally on its own.
What are therefore the reasons for the rally and can it continue?
1. Technical factors: massively oversold and undervalued, even as the company needs fresh equity and credit financing. More than 10mn shares short (= 10% of issued equity) may have triggered some panic short covering.
2. Scientific progress: Cytori for example started enrollment in a knee osteoarthritis clinical trial, got EU orphan drug status (given for indications with relatively small number of patients) in scleroderma and added more clinical sites in their US scleroderma trial.
3. Ongoing rumors about either big investors (as e.g. Blackrock, Sabby) building stakes, or old (Lorem) or new (Roche) pharma related companies take Cytori over and/or are close to partnership deals.
For me, it's most likely a combination of all: Additional to the technical factors, the orphan drug status in EU, given by an independent authority, clearly signals, that ADRCs (fat cells) may work in scleroderma. Expanding the clinical trial centers from 12 to 20 in the US scleroderma trial is very positive, as out of 35 centers in the whole US, 20 get used to the procedure and in case of a positive trial result, can immediately commence treating their patients - Cytori should be able to get more than 50% market share within very short time, once it would be approved. But all that - positive scientific news, is not really breakthrough and was somewhat to be expected (remember, that was the reason why I continued to recommend the shares, even as the stock fell massively). Thus, I believe that also some big buyers have triggered the rally. Weather its a potential operating partner, or "just" some smart investors, I can not judge. But there is no smoke without fire in my opinion.
How will it continue?
If there is no news within the next days, I expect some profit taking, which could bring the shares down by some 20-30%. So, if you bought some share at the $ 0.50 level, why not selling at above $ 1.30. Not bad within a few days. If you did follow my earlier recommendations, unfortunately you are still in losses. Stick to it, as buying Cytori was always a long-term investment, with the shares to move to $ 5, $ 10 or even more, as the technology (regenerative medicine) is likely to change treatment options for many indications (scleroderma, urinary incontinence, wound healing, heart failure....).
Potential positive news within the next months: 2014 results conference - with bigger focus on the future than on 2014 in itself. Some data from the heart failure trial (Athena), More anecdotal evidence from Okyanos clinic, which is treating real patients in plenty of indications. Progress in Japan, in clinical trials, but also in coming closer to the market. Approval in China and first sales in China, Australia... (Lorem). And while I am hoping for partnership deals (for example in scleroderma) and or someone taking-over Cytori, it is almost my greatest fear, that someone would buy them for $ 2-3, far below my $ 10 plus long-term hope.
Lots of green on my Level 2
"These findings could ultimately have significant implications in how we treat advanced stage breast cancer patients," said Kevin Kalinsky, M.D., Assistant Professor of Medicine at Columbia University Medical Center and first author of the paper. "Since it is not always feasible to obtain metastatic tissue from breast cancer patients, CTCs are an attractive alternative source of tumor material. CTCs provide real-time information about the HR status of a tumor that can be monitored more readily on an ongoing basis."
The ultimate goal of CTC evaluation is to assist physicians with making treatment decisions, such as the role of anti-estrogen therapy. The Columbia study shows that CTCs afford diagnostic results that are comparable to tumor tissue.
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers CLIA validated tests for breast, lung and gastric cancer and plans to offer additional assays for colorectal, prostate and other solid tumors based on its proprietary technology platforms in the future.
About Kevin Kalinsky, M.D., M.S.
Dr. Kalinsky received his undergraduate B.A. from Emory University. He received his M.D. from the Medical University of South Carolina and completed his Internal Medicine internship and residency at Tufts Medical Center. During his Hematology/Oncology fellowship at Tufts Medical Center, he received the Abby Shevitz Award for Young Physician's in Hematology/Oncology. In Boston, he also trained as a breast cancer clinical research fellow at Massachusetts General Hospital. In addition, he completed an advanced oncology fellowship in breast cancer at Memorial Sloan-Kettering Cancer Center.
Dr. Kalinsky cares for patients diagnosed with breast cancer and teaches on the Breast Oncology service. His research involves the development of early phase clinical trials to assess novel therapeutic agents in breast cancer. The goal of his research is to translate findings developed at the bench to clinical trials for study at the bedside. His work is funded by a number of sources, including the National Institute of Health and SWOG/The Hope Foundation.
Will pop like a coiled spring
smart buys believe in this company. Huge price targets speak volume.